Ipatasertib
Ipatasertib is an experimental cancer drug in development by Roche. It is a small molecule inhibitor of AKT, which is a key component of the PI3K/AKT pathway. Ipatasertib was discovered by Genentech in collaboration with Array Biopharma and is currently in phase III trials for treatment of breast cancer.
In vitro, ipatasertib showed activity against all three isoforms of Akt.